linjc16/ctgov huggingface dataset:
Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study

Study Overview
=================
Brief Summary
-----------------
It has been argued that social relationships are important to health and well-being. This study will investigate links between social networks and cardiovascular disease risk factors in South Asians, the second fastest growing ethnic group in the US and one with disparate rates of coronary heart disease. Identifying and understanding the links between social networks and cardiovascular disease is key to the development and testing of family- and community-level prevention interventions for minorities.

Detailed Description
-----------------
This study will use mixed-methods to investigate links between social networks and cardiovascular disease risk factors in South Asians, the second fastest growing ethnic group in the US and one with disparate rates of coronary heart disease. Identifying and understanding the links between social networks and cardiovascular disease is key to the development and testing of family- and community-level prevention interventions for minorities.

Official Title
-----------------
Social and Cultural Influences on Cardiovascular Disease Risk in South Asians

Conditions
-----------------
Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants enrolled in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. Exclusion Criteria: People not enrolled in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MASALA study<br>Mediators of Atherosclerosis in South Asians Living in America (MASALA) study participants will be invited to participate in this ancillary study. Objective of MASALA study: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40-79 years at 2 US clinical field centers. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of MASALA participants with high kin density |  | Two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiovascular Disease, Social network, South Asians
Atopy Patch Test in Children With Atopic Dermatitis

Study Overview
=================
Brief Summary
-----------------
Positive reactions in atopy patch test in children with atopic dermatitis.

Detailed Description
-----------------
The prevalence of food allergy seems to be increasing, which might explain the increased demand for reliable evaluation of patients with suspected food-related gastrointestinal symptoms. Little is known about the diagnostic accuracy of atopy patch tests(APT) in the clinical practice. APT seems to have a better specificity than the IgE methods and seems to reflect late-phase clinical reactions.The aims of this study were to evaluate: (i) The prevalence of positive reaction of APTs for atopic dermatitis (ii)Positive reaction of APT compare with skin prick test. (iii)Positive reaction of APT using lyophilized food vs commercially available food extracts. (iv)Side effect or adverse

Official Title
-----------------
Atopy Patch Test in Children With Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis, Food Allergy

Intervention / Treatment
-----------------
* Other: atopic patch test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had history of atopic dermatitis Exclusion Criteria: Who have dermographism Who have chronic disease eg. autoimmune disease, immune deficiency, cancer or allergic disease Pregnant women Who receive antihistamine, topical steroid and systemic steroid > 20 mg/day within 7 days prior study

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: atopic patch test|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| atopic patch test in atopic dermatitis children |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atopic dermatitis, atopic patch test
Human Blood Cell Disorders Tissue Bank

Study Overview
=================
Brief Summary
-----------------
The Human Blood Cell Disorder Tissue Bank will provide a convenient, comprehensive source of tissue containing populations of human blood cells from patients with various types of lymphoid, myeloid, and erythroid proliferative diseases as well as other associated conditions. The tissue bank will continue to be an invaluable asset for understanding of the biology of multiple blood cell disorders involving several cell types as well as the physiology of normal cellular counterparts affected in these disorders. Internal and external investigators will be able to utilize this tissue to test hypotheses relating to the immunologic, virologic, genetic, and molecular properties of these abnormal cells as well as normal cells from normal unaffected family members or normal aged matched subjects to provide better comparisons.

Official Title
-----------------
Human Blood Cell Disorders Tissue Bank

Conditions
-----------------
Human Blood Cell Disorders, Lymphoid, Myeloid and Erythroid Proliferative Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants or participant's Legally Authorized Representatives (LAR) must be able to understand and render voluntary, written informed consent. Patients must be able to contribute the required amount of blood and/or tissue without compromising their well-being or care. Participants must be willing to be contacted again for consideration of additional studies in the future, such as a blood draw or another action (e.g., bone marrow aspiration and/or biopsy) that would be done as part of their standard of care. Exclusion Criteria: Patients who are known to be anemic, with hemoglobin <8.0g/dl. Patients who are known to be infected with HIV.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Human Blood Cell Disorders<br>Human Blood Cell Disorders Tissue Bank | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accumulate tissue from patients with various blood disorders, including but not restricted to lymphoproliferative, myeloproliferative, and erythroproliferative conditions. |  | Indefinite | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Develop a database of at least 10,000 subjects who have donated samples for research as well as DNA banking, and who are willing to be contacted again for consideration of additional studies in the future. |  | Indefinite | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Human Blood Cell Disorders, lymphoid, myeloid and erythroid proliferative disease
A Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi

Study Overview
=================
Brief Summary
-----------------
In this study nurses will be taught regarding Modified Early Warning Score and how to mark the involved physiological parameters in the MEWS chart and then scoring will be given i.e MEWS score and according to the score intervention would be taken by nurses by communicating with other health team members. this scoring will allow nurses to assess early deterioration and early ICU admission and at last nurses will be asked regarding the barriers or facilitators they faced while performing MEWS score.

Official Title
-----------------
A Quasi Experimental Study to Assess the Impact of Implementing Modified Early Warning Score in Terms of Competency and Self-efficacy of Nurses at ILBS, Delhi

Conditions
-----------------
Liver Diseases

Intervention / Treatment
-----------------
* Other: training porogram


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: registered nurses working in general, semi-private and private ward nurses willing to participate Exclusion Criteria: registered nurses who will not be present at the time of data collection. pull out staffs.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: one group pre-test post-test design.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: staff nurses<br>firstly pre-test would conducted for the group then after 7 days post-test would be conducted for the same group intervention which will be given: training on modified early warning score to staff nurses and marking of physiological parameters on MEWS chart | Other: training porogram<br>* training on modified early warning signs will be given to staff nurses and they will be asked to mark physiological parameters on MEWS chart and identify detrioration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to assess the impact of MEWS on competency and self-efficacy of nurses before and after implementing MEWS | pre-test would be taken to assess previous level and post-test to measure the change in competency | 7 days |
Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy

Study Overview
=================
Brief Summary
-----------------
The medical records of 393 eyes of 326 patients with severe proliferative diabetic retinopathy were reviewed. Higher cutting rate instruments (5000 cut per minute) were used in 174 eyes and conventional instruments in 219 eyes (2500 cut per minute). The visual outcome and incidences of intraoperative and postoperative complications were compared.

Official Title
-----------------
Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy

Conditions
-----------------
Proliferative Diabetic Retinopathy

Intervention / Treatment
-----------------
* Procedure: Vitrectomy for proliferative diabetic retinopathy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria were patients who had persistent vitreous hemorrhage, fibrovascular proliferation affecting the macula, or tractional RD and who had a follow-up for more than 6 months. Exclusion Criteria: The eyes with follow-up less than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Higher cutting rate group<br>Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy | Procedure: Vitrectomy for proliferative diabetic retinopathy<br>* 25-gauge vitrectomy<br>|
| Conventional cutting rate group<br>Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy | Procedure: Vitrectomy for proliferative diabetic retinopathy<br>* 25-gauge vitrectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal reattachment |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetic retinopathy
Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess the distribution of the most frequent types of human papillomavirus in women diagnosed with invasive cervical cancer in New Zealand.

Official Title
-----------------
Hospital-based Epidemiological Study on the Distribution of Human Papillomavirus (HPV) Types in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) in New Zealand

Conditions
-----------------
Cervical Cancer

Intervention / Treatment
-----------------
* Other: Testing of archived cervical cancer tissue samples
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A female aged 18 years and above at the time of cervical specimen collection, and currently residing in New Zealand. Histological diagnoses of invasive cervical cancer stage IB or greater, within at least the last 3 years. Written informed consent obtained from the subject/ next of kin/ Legally acceptable representative. Availability of cervical specimen on which the diagnosis was made prior to any chemotherapy or radiotherapy. The cervical specimen should be of appropriate size and with regular tissue specimens. The cervical specimen should be adequately preserved. All links to the subject's identity should be removed from the paraffin block. Exclusion Criteria: Not Applicable.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>Subjects diagnosed with invasive cervical cancer | Other: Testing of archived cervical cancer tissue samples<br>* Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.<br>Other: Data collection<br>* Log sheet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of HPV-16 and HPV-18 in women with invasive cervical cancer |  | At least the last 3 years from the time of study start | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of other high-risk HPV types in women with invasive cervical cancer |  | At least the last 3 years from the time of study start | 
| Occurrence of HPV-16/ HPV-18 co-infection with other high-risk HPV types in women with invasive cervical cancer |  | At least the last 3 years from the time of study start | 
| Occurrence of low-risk HPV types in women diagnosed with invasive cervical cancer |  | At least the last 3 years from the time of study start | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Invasive cervical cancer, Human papillomavirus
Bishop Score, Cervical Length and Multiple Proteins in Cervicovaginal Fluid at 40 Weeks to Predict Onset of Labor

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare Bishop score, sonographic cervical length and multiple proteins in cervicovaginal fluid at 40 weeks gestation to predict time to spontaneous labor and mode of delivery.

Conditions
-----------------
Prolonged Labor

Intervention / Treatment
-----------------
* Other: Ultrasound and digital cervical examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women between 39+6 and 40+1 weeks of gestation singleton pregnancy viable fetus with vertex presentation intact amniotic membranes no pregnancy complications absence of labor no history of previous uterine surgery planned vaginal delivery
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women attending antenatal clinic<br>Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation. | Other: Ultrasound and digital cervical examination<br>* Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Onset of labor/delivery ≤10days |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cesarean delivery in labor | Time to onset of spontaneous labor Postterm delivery (≥40 + 11 weeks of pregnancy) The rate of cesarean delivery | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Onset of labor, Bishop score, Cervical length, Multiple proteins, Cervicovaginal fluid
NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Study Overview
=================
Brief Summary
-----------------
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Detailed Description
-----------------
Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

Official Title
-----------------
Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients

Conditions
-----------------
Non-small Cell Lung Cancer

Intervention / Treatment
-----------------
* Other: Time


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy Exclusion Criteria: EGFR mutant positive Alk mutant positive

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Time|Different detecting time|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| numbers of immune cells | detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| numbers of tumor mutations | detecting numbers of tumor mutations before first-line chemotherapy, after two cycles chemotherapy and after disease progression | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NGS, RNAseq
Correlation Between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population

Study Overview
=================
Brief Summary
-----------------
The study evaluated the prevalence, presentation, management, and prognosis of coronary heart disease differ according to sex.

Detailed Description
-----------------
The study included 884 patients enrolled in our institute between June 2002 and May 2016. Considering psychosocial factors, treatments, and the outcomes in men versus those in women with acute aortic dissection, explored the association of sex with psychosocial characteristics and mortality risk. Of 884 patients, 211 (23.9%) were women. The median duration of follow-up was 2.9 years (25th -75th percentiles: 1-4 years ).

Official Title
-----------------
Correlation Between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population

Conditions
-----------------
Sex Role, Acute Aortic Dissection

Intervention / Treatment
-----------------
* Drug: drug
* Procedure: Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute aortic dissection Exclusion Criteria: Chronic aortic dissection

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| male<br>Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin | Drug: drug<br>* Application bracket<br>* Other names: thoracic endovascular aortic repair;Procedure: Surgery<br>* Surgery<br>|
| female<br>Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin | Drug: drug<br>* Application bracket<br>* Other names: thoracic endovascular aortic repair;Procedure: Surgery<br>* Surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The outcome measure describes aortic disease-related death，aortic dissection, paraplegia, myocardial ischemia, renal insufficiency and other aortic complications. | The study's primary endpoint during the follow up was the composite of aortic disease-related death, aortic dissection, paraplegia, myocardial ischemia, renal insufficiency and other aortic complications during follow-up. | 2.9years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sex, aortic dissection, treatment